Calliditas Therapeutics (CALT)
NASDAQ:CALT
Holding CALT?
Track your performance easily

Calliditas Therapeutics (CALT) Stock Forecast & Price Target

125 Followers
See the Price Targets and Ratings of:

CALT Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Calliditas
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CALT Stock 12 Month Forecast

There Are No Analyst Ratings for CALT In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

CALT Financial Forecast

CALT Earnings Forecast

Next quarter’s earnings estimate for CALT is $0.15 with a range of -$0.22 to $0.52. The previous quarter’s EPS was -$0.17. CALT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.47% of the time in the same period. In the last calendar year CALT has Underperformed its overall industry.
Next quarter’s earnings estimate for CALT is $0.15 with a range of -$0.22 to $0.52. The previous quarter’s EPS was -$0.17. CALT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.47% of the time in the same period. In the last calendar year CALT has Underperformed its overall industry.

CALT Sales Forecast

Next quarter’s sales forecast for CALT is $57.41M with a range of $50.80M to $66.42M. The previous quarter’s sales results were $52.37M. CALT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.92% of the time in the same period. In the last calendar year CALT has Outperformed its overall industry.
Next quarter’s sales forecast for CALT is $57.41M with a range of $50.80M to $66.42M. The previous quarter’s sales results were $52.37M. CALT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.92% of the time in the same period. In the last calendar year CALT has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$39
Hold
-2.89%
Downside
Downgraded
05/30/24
Calliditas Therapeutics downgraded to Neutral from Buy at CitiCalliditas Therapeutics downgraded to Neutral from Buy at Citi
Kepler Capital
$20.32
Hold
-49.41%
Downside
Downgraded
05/29/24
LifeSci Capital
$44$39
Hold
-2.89%
Downside
Downgraded
05/28/24
Maintaining Hold Rating Amidst Calliditas Acquisition by Asahi Kasei: Assessing the Premium Offer and Strategic Fit
Stifel Nicolaus
$55$40
Hold
-0.40%
Downside
Downgraded
05/28/24
Analysts Offer Insights on Healthcare Companies: Allakos (NASDAQ: ALLK), Calliditas Therapeutics (NASDAQ: CALT) and Clene (NASDAQ: CLNN)
Jefferies
$58$39
Hold
-2.89%
Downside
Downgraded
05/28/24
Maintaining Hold on Calliditas: Assessing Acquisition Fairness Amid Evolving IgAN Market Dynamics
H.C. Wainwright
$45$39
Hold
-2.89%
Downside
Downgraded
05/28/24
Asahi Kasei's Acquisition of Calliditas Therapeutics: A Hold Rating with Revised Price Target

CALT Analyst Recommendation Trends

Rating
Dec 23
Feb 24
Mar 24
Apr 24
May 24
Strong Buy
9
12
9
7
7
Buy
0
0
0
0
0
Hold
0
0
0
0
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
12
9
7
13
In the current month, CALT has received 7 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CALT average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

CALT Stock Forecast FAQ

What is CALT’s average 12-month price target, according to analysts?
Currently, no data Available
What is CALT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CALT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is CALT a Buy, Sell or Hold?
      Currently, no data Available
      What is Calliditas Therapeutics’s price target?
      Currently, no data Available
      What do analysts say about Calliditas Therapeutics?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of CALT?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis